- Open Access
Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease
© Devi et al; licensee BioMed Central Ltd. 2010
- Received: 28 July 2010
- Accepted: 8 November 2010
- Published: 8 November 2010
It is hypothesized that complex interactions between multiple environmental factors and genetic factors are implicated in sporadic Alzheimer's disease (AD); however, the underlying mechanisms are poorly understood. Importantly, recent evidence reveals that expression and activity levels of the β-site APP cleaving enzyme 1 (BACE1), which initiates amyloid-β (Aβ) production, are elevated in AD brains. In this study, we investigated a molecular mechanism by which sex and stress interactions may accelerate β-amyloidogenesis and contribute to sporadic AD.
We applied 5-day restraint stress (6 h/day) to the male and female 5XFAD transgenic mouse model of AD at the pre-pathological stage of disease, which showed little amyloid deposition under non-stressed control conditions. Exposure to the relatively brief behavioral stress increased levels of neurotoxic Aβ42 peptides, the β-secretase-cleaved C-terminal fragment (C99) and plaque burden in the hippocampus of female 5XFAD mice but not in that of male 5XFAD mice. In contrast, significant changes in the parameters of β-amyloidosis were not observed in the cerebral cortex of stressed male or female 5XFAD mice. We found that this sex- and brain region-specific acceleration of β-amyloidosis was accounted for by elevations in BACE1 and APP levels in response to adverse stress. Furthermore, not only BACE1 mRNA but also phosphorylation of the translation initiation factor eIF2α (a proposed mediator of the post-transcriptional upregulation of BACE1) was elevated in the hippocampus of stressed female 5XFAD mice.
Our results suggest that the higher prevalence of sporadic AD in women may be attributable to the vulnerability of female brains (especially, the hippocampus) to stressful events, which alter APP processing to favor the β-amyloidogenesis through the transcriptional and translational upregulation of BACE1 combined with elevations in its substrate APP.
- Amyloid Precursor Protein
- Restraint Stress
- Amyloid Precursor Protein Processing
- 5XFAD Mouse
- Behavioral Stress
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly. One of the hallmark pathologies of AD is the senile plaque that is constituted of amyloid-β (Aβ) peptides. Although mutations in three different genes favoring the overproduction of Aβ are known to cause early-onset familial AD (FAD) [1, 2], the etiology of sporadic AD that accounts for the majority of AD cases remains unclear. It is hypothesized that complex interactions between the genetic background and various environmental factors underlie sporadic AD [3, 4] and a stressful lifestyle may represent one of the important risk factors for AD . Elderly individuals prone to psychological distress are more likely to develop AD than those not prone to distress, and this trait is also associated with a more rapid progression of disease [6, 7]. Consistent with the clinical observations, recent studies demonstrated that exposure to adverse behavioral stress accelerates the development of amyloid pathology and worsens memory decline in transgenic mouse models of AD [8–11], although the underlying molecular mechanisms have not been investigated in detail.
Meanwhile, it is also known that women have a higher risk of developing AD than do men. Although the longevity effect might be a factor in the preponderance of women with AD, the sex difference in AD prevalence remains even after age adjustment [12–14]. Interestingly, not only the sex but also the brain region represents a determinant of neuronal responses to stressful experience. For example, the hippocampus is a structure highly sensitive to stressor and is enriched with glucocorticoid receptors . Furthermore, opposite effects of stress on hippocampal functions have been reported; an acute stressful event facilitates learning and increases dendritic spine density in male rats, whereas learning and spine density deteriorate after exposure to the same stressor in female rats [16–18]. Therefore, it is important to determine whether and how gender and adverse stress may interact to modify disease progression in different brain regions of AD transgenic mice.
The β-cleavage of amyloid precursor protein (APP) by BACE1 (β-site APP cleaving enzyme 1) initiates the generation of neurotoxic Aβ peptides. Notably, evidence is accumulating that increased levels of cerebral BACE1 and/or APP expression may be crucial contributing factors in developing sporadic AD [19–22]. In this study, we tested the hypothesis that behavioral stress may trigger the upregulation of BACE1 and/or APP, which may lead to differential acceleration of β-amyloidogenesis in the hippocampus and cerebral cortex of male and female subjects. Specifically, 5XFAD transgenic model mice at 3 months of age, which exhibit little or only faint amyloid pathology under normal conditions , were exposed to 5-day restraint stress, and we compared levels of BACE1, APP, its β-cleavage products and plaque burden between stressed and non-stressed subjects. We clearly demonstrate that the hippocampus of female 5XFAD mice shows the dramatic acceleration of β-amyloidogenesis with significantly elevated levels of both BACE1 and APP expression following the relatively brief stress treatment, providing a molecular basis for the higher prevalence and incidence of sporadic AD in women. Furthermore, our results also suggest that not only transcriptional but also translational mechanisms through phosphorylation of eukaryotic initiation factor-2α (eIF2α) may underlie BACE1 elevation associated with adverse stress during AD progression.
Behavioral stress accelerates Aβ accumulation in 5XFAD mice in a sex- and brain region-dependent manner
Behavioral stress elevates BACE1 and APP levels in 5XFAD mice in a sex- and brain region-dependent manner
Transcriptional and translational mechanisms underlie sex- and brain region-dependent BACE1 elevation in 5XFAD mice following behavioral stress
Very few AD cases can be attributable to genetic causes, while the etiology of sporadic AD that constitutes the majority of AD cases remains unclear [3, 4]. Nevertheless, most transgenic models of AD are created based on a simple genetic association between the rare inherited form of FAD and excessive Aβ production and do not encompass acquired characteristics [27–30]. Many non-genetic factors including age, lifestyle (e.g., daily stress and diets), medical history and education have been reported to contribute to increasing the risk for AD [31, 32]. Epidemiological investigations also show gender differences in the incidence and prevalence of AD with females being at higher risk [12–14], although a biological foundation for gender differences remains to be determined. In this study, we applied a relatively brief behavioral stress to male and female 5XFAD transgenic model mice at the pre-pathological stage of disease that shows little or only faint amyloid deposition, and tested the hypothesis that sex and stress interactions may represent a key mechanism underlying sporadic AD and rendering women more prone to develop AD.
Our results clearly demonstrated that 5-day exposure to restraint stress increased levels of Aβ42 peptides, a pathogenic Aβ species that is more hydrophobic and has the propensity to assemble into neurotoxic oligomers and aggregates [33–35], in the hippocampus of female 5XFAD mice but not in male 5XFAD mice. Meanwhile, the same stress treatment did not significantly affect Aβ42 levels in the cerebral cortex of male or female 5XFAD mice. Accordingly, amyloid plaque formation was also accelerated specifically in the female 5XFAD hippocampus following restraint stress. Interestingly, previous studies applied much longer stress treatments (e.g., several months of immobilization and/or isolation) to APP transgenic mice and showed that such prolonged stress exposures resulted in elevated Aβ concentrations and pathology in both the hippocampus and cortex without distinction based on sex [8–11]. Therefore, it should be noted that only 5-day exposure to restraint stress was sufficient to significantly elevate levels of Aβ42 and plaque load in 5XFAD mice in this study. Of particular importance, such a brief stress treatment revealed that the hippocampus of females is vulnerable and prone to develop amyloid deposits in response to adverse behavioral stressors. These findings support the idea that the higher prevalence of sporadic AD in women may be, at least in part, attributable to the vulnerability of female brain, especially the hippocampus, to stress mechanisms that favor β-amyloidogenic processing of APP. This is also consistent with the observation that hippocampal Aβ deposition is one of the earliest features of AD .
What mechanisms underlie the sex- and brain region-specific acceleration of Aβ accumulation following brief stress exposure? Previous studies demonstrate a sex difference in stress effects and estrogens are known to potentiate the glucocorticoid secretion under stress conditions [37, 38]. This mechanism may represent the key component of the stress response that promotes β-amyloidosis more profoundly in female 5XFAD brains. Alternatively, recent studies have started to reveal the involvement of gender-specific molecular signaling processes or sex chromosome gene expression in addition to estrogen effects in causing sex differences in neuronal function [39, 40]. Further study is needed to address the precise mechanisms including interactions between sex hormones and different stress mediators linking with changes in neuronal amyloidogenic processing of APP associated with AD.
Importantly, we found that BACE1 expression was elevated specifically in the hippocampus of stressed female 5XFAD mice in accordance with increased levels of Aβ42 and plaque burden. It has been reported that protein and/or activity levels of BACE1 become elevated in brains of sporadic AD patients [19–21, 41] and 5XFAD mice [26, 42–44] as disease progresses into the severer pathological stage with established amyloid plaques. Recent studies including ours demonstrate that phosphorylation of the translation initiation factor eIF2α plays a critical role in mediating the post-transcriptional upregulation of BACE1 associated with AD [25, 26]. Increases in phospho-eIF2α levels occur in brains of sporadic AD and advanced pathological stages of APP transgenic mice including the 5XFAD model [24–26, 45, 46] and are shown to correlate with BACE1 elevation [25, 26]. In the present study, baseline phospho-eIF2α levels of non-stressed 5XFAD mice at the pre-pathological stage were not significantly different from those of wild-type control mice, while they were increased by 5-day restraint stress exposure specifically in the hippocampus of female 5XFAD mice in line with BACE1 elevation. Therefore, these results suggest that the phospho-eIF2α-dependent translational upregulation of BACE1 in response to behavioral stressors may represent an important molecular mechanism by which environmental factors initiate β-amyloidogenesis before significant Aβ deposition occurs during the early phase of sporadic AD. This hypothesis is strongly supported by our recent observation that the increase in phospho-eIF2α induced by Sal 003, a specific inhibitor of its phosphatase, elevates BACE1 levels in younger 5XFAD mice, which have not yet showed BACE1 upregulation at basal levels concomitant with only marginal increases in eIF2α phosphorylation .
In addition to the translational mechanism, transcriptional control of BACE1 may also be implicated in AD pathogenesis [47, 48]. In this study, we showed the increase of BACE1 mRNA level in the hippocampus of stressed female 5XFAD mice compared with that of non-stressed controls, suggesting a possibility that transcriptional mechanisms may also contribute to the BACE1 elevation associated with adverse behavioral stress. Our results are consistent with the findings that the promoter region of BACE1 gene contains glucocorticoid responsive elements  and that glucocorticoid administration facilitates Aβ production possibly via increases in transcription of the BACE1 gene through this binding site . Some studies with postmortem human brains report elevations in BACE1 mRNA levels associated with sporadic AD [21, 51], while others show no changes in mRNA despite the increased levels of BACE1 activity and protein [22, 52–54]. Therefore, the mechanisms underlying BACE1 elevation in the sporadic AD brain remain controversial, which may be accounted for by differences in complex environmental factors mainly responsible for the disease progression. Our mouse model study suggests that both transcriptional and translational mechanisms may underlie BACE1 elevations associated with adverse stress during the development of AD.
Intriguingly, we also found that stress-responsive increases in APP expression levels occurred only in the hippocampus of female 5XFAD mice. Therefore, it seems likely that elevations in both BACE1 and its substrate APP work cooperatively to enable dramatic increases in the intermittent β-cleaved C-terminal fragment C99 and the acceleration of Aβ42 production and plaque formation in the hippocampus of female 5XFAD mice following 5-day exposure to behavioral stress. Given that Aβ and C99 peptides are amyloidogenic and can induce synaptic failure, neurodegeneration and memory loss [34, 55–59], behavioral stress-dependent elevations in both β-cleavage products through BACE1 and APP upregulation have important implications for the pathogenesis of sporadic AD and the progression of neuronal dysfunction. Our findings are in agreement with recent reports showing that exposure to stress-level glucocorticoids (daily injections of dexamethasone for 7-21 days) elevates both BACE1 and APP levels leading to accelerated C99 production and Aβ accumulation [50, 60, 61]. However, these pharmacologically induced stress responses seem more robust than the behavioral stress regimen applied in this study as the changes are observed in brains of male subjects including 3xTg-AD transgenic model mice and middle-aged wild-type mice or rats. In any case, our present study combined with others indicates that elevated levels of glucocorticoids found in sporadic AD brains [62–64] may not only be a consequence of the pathology but also play a causal role in triggering β-amyloidogenesis through BACE1 and APP elevations during earlier stages of disease progression.
Our mouse model study clearly demonstrates that the responsiveness of brains (especially, hippocampal neurons) to stress conditions, which shift APP processing toward β-amyloidogenesis by upregulating BACE1 and its substrate APP, represents a crucial contributing factor in the development of sporadic AD and may account for a mechanism underlying the increased prevalence of women to develop AD. Moreover, our data also suggest that transcriptional and translational mechanisms may underlie BACE1 elevation in response to adverse stressors, supporting the idea that therapeutic interventions aimed at suppressing stress-related signaling pathways (e.g., reduction of glucocorticoids or eIF2α phosphorylation) may be beneficial for slowing down AD progression.
We used 5XFAD transgenic mice that co-overexpress FAD mutant forms of human APP (the Swedish mutation: K670N, M671L; the Florida mutation: I716V; the London mutation: V717I) and presenilin-1 (PS1: M146L, L286V) transgenes under transcriptional control of the neuron-specific mouse Thy-1 promoter (Tg6799 line) [23, 65]. 5XFAD lines (B6/SJL genetic background) were maintained by crossing hemizygous transgenic mice with B6/SJL F1 breeders (Taconic, Hudson, NY). 5XFAD transgenic mice used were hemizygotes with respect to the transgene and non-transgenic wild-type littermate mice served as controls. Genotyping was performed by PCR analysis of tail DNA. All experiments were done blind with respect to the genotype of the mice, and were conducted with the approval of the Nathan Kline Institute Animal Care and Use Committee.
Stressed 5XFAD mice were individually placed in a well-ventilated plastic tube (Diameter: 3.8 cm) (541-RR, Plas-Labs, Lansing, MI) and restrained for 6 h per day during 5 consecutive days. After each stress session, the mice were returned to their cage where they were housed in isolation with free access to food and water. Twenty-four hours after the last exposure to restraint stress, brain samples were collected. The timing of stress treatments was arranged so that 5XFAD mice were precisely at 3 months of age when sacrificed. Non-stressed control mice were kept group-housed in their home cage and were sacrificed for analysis at 3 months of age.
Sandwich Aβ ELISA was performed as described previously [66, 67]. Briefly, each hemibrain sample was extracted in 8X cold 5 M guanidine HCl plus 50 mM Tris HCl (pH 8.0) buffer, and centrifuged at 20,000 g for 1 h at 4°C to remove insoluble material. Final guanidine HCl concentrations were below 0.1 M. Protein concentrations were determined by a BCA protein assay kit (Pierce, Rockford, IL). To quantitate total levels of cerebral Aβ42, supernatant fractions were analyzed by a well-established human Aβ42 ELISA kits (KHB3441, Invitrogen, Carlsbad, CA) according to the protocol of the manufacturer. Optical densities at 450 nm of each well were read on a VersaMax tunable microplate reader (Molecular Devices, Sunnyvale, CA), and sample Aβ42 concentrations were determined by comparison with the standard curves. Aβ42 concentration values were normalized to total brain protein concentrations and expressed in nanograms per milligram of total protein.
Mice were transcardially perfused with 4% paraformaldehyde in phosphate buffered saline (PBS) under deep isoflurane anesthesia. The brain was removed and sectioned coronally at 40 μm on a vibratome (VT1200, Leica Microsystems, Wetzlar, Germany), and successive sections were stored in PBS containing 0.01% sodium azide at 4°C. Four sections per mouse were stained by the avidin-biotin peroxidase complex method for immunohistochemical analysis of amyloid deposition in the hippocampus and cerebral cortex [66, 67]. Each section was separated by ~120 μm and taken at levels of -1.5/-1.9 mm to bregma according to the mouse brain atlas of Franklin and Paxinos . The sections were incubated overnight at 4°C with monoclonal anti-Aβ1-16 antibody (1:200; 6E10, Signet, Dedham, MA). The ABC kit (PK-2200, Vector Laboratories, Burlingame, CA) was utilized with 3,3'-diaminobenzidine tetrahydrochloride as a chromogen to visualize the reaction product. The sections were then mounted on charged slides, dehydrated in a series of alcohol, cleared in xylene, and covered with a coverslip. Light microscopy was conducted on an Axioskop 2 microscope equipped with an AxioCaM HRc digital camera (Zeiss, Munich, Germany) for capturing images. Semi-quantitative analysis was performed using AxioVision imaging software with the AutoMeasure module (Zeiss). Identified objects after thresholding were individually inspected to confirm the object as a plaque or not in a blinded manner. Percentage area occupied by Aβ deposits in the hippocampus and cortex was assessed bilaterally, and the average of the individual measurements from each mouse was calculated to compare plaque load between the stressed and non-stressed 5XFAD mice.
Hippocampal and cortical samples were taken from the mice under deep isoflurane anesthesia and were snap-frozen for Western blot analysis [66, 67]. Each sample was homogenized in 5 volumes of modified RIPA buffer containing 150 mM NaCl, 50 mM Tris HCl (pH 8.0), 1 mM EDTA, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS and protease/phosphatase inhibitor cocktails (Calbiochem, La Jolla, CA), and centrifuged at 10,000 g for 10 min to remove any insoluble material. Protein concentrations were determined by a BCA kit (Pierce), and 20-50 μg of protein was run on 4-12% NuPAGE gels (Invitrogen) and transferred to nitrocellulose membrane. After blocking, membranes were probed with anti-BACE1 (1:1,000, MAB5308, Millipore, Billerica, MA), an antibody that recognizes C-terminal epitope in APP (1:1,000, C1/6.1, kindly provided by Dr. Paul Mathews, Nathan Kline Institute) to detect full-length APP/C-terminal fragments, anti-phospho-eIF2α(Ser51) (1:1,000, #3398, Cell Signaling Technology, Danvers, MA), anti-eIF2α (1:1,000, #9722, Cell Signaling Technology) or anti-β-actin (1:15,000, AC-15, Sigma, St. Louis, MO). They were then incubated with horseradish peroxidase-conjugated secondary IgG. Immunoblot signals were visualized by an ECL chemiluminescence substrate reagent kit (Pierce) and were quantified by densitometric scanning and image analysis using Quantity One software (Bio-Rad Laboratories, Hercules, CA).
qPCR was performed in triplicate on frozen hippocampal samples as described previously [69, 70]. TaqMan qPCR primers were utilized for mouse BACE1 mRNA (Mm00478671_m1, Applied Biosystems, Foster City, CA) and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Mm99999915_g1, Applied Biosystems). Samples were assayed on a real-time qPCR cycler (7900HT, Applied Biosystems) in 96-well optical plates covered with optical adhesive film. Standard curves and cycle threshold were generated using standards obtained from total mouse brain RNA. The delta delta cycle threshold (ddCT) method was employed to determine relative gene level differences between stressed and non-stressed 5XFAD mice with GAPDH qPCR products used as a control, and expression levels were presented as percentage of non-stress controls. Negative controls consisted of the reaction mixture without input RNA.
The significance of differences between the groups was determined by a one-way ANOVA and post-hoc Fisher's PLSD tests were performed when appropriate. Data were presented as mean ± SEM and the level of significance was set for p value less than 0.05.
This work was supported by National Institutes of Health grant R01 MH067251 (M.O.) and Alzheimer's Association grant IIRG-08-91231 (M.O.).
- Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997, 20: 154-159. 10.1016/S0166-2236(96)01030-2.View ArticlePubMedGoogle Scholar
- Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81: 741-766.PubMedGoogle Scholar
- Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368: 387-403. 10.1016/S0140-6736(06)69113-7.View ArticlePubMedGoogle Scholar
- Wu J, Basha MR, Zawia NH: The environment, epigenetics and amyloidogenesis. J Mol Neurosci. 2008, 34: 1-7. 10.1007/s12031-007-0009-4.View ArticlePubMedGoogle Scholar
- Rothman SM, Mattson MP: Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromolecular Med. 2010, 12: 56-70. 10.1007/s12017-009-8107-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson RS, Barnes LL, Bennett DA, Li Y, Bienias JL, Mendes de Leon CF, Evans DA: Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology. 2005, 64: 380-382.View ArticlePubMedGoogle Scholar
- Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA: Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology. 2006, 27: 143-153. 10.1159/000095761.View ArticlePubMedGoogle Scholar
- Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, Lee SH, Emson PC, Suh YH: Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 2006, 20: 729-731.PubMedGoogle Scholar
- Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG: Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience. 2004, 127: 601-609. 10.1016/j.neuroscience.2004.05.040.View ArticlePubMedGoogle Scholar
- Dong H, Yuede CM, Yoo HS, Martin MV, Deal C, Mace AG, Csernansky JG: Corticosterone and related receptor expression are associated with increased β-amyloid plaques in isolated Tg2576 mice. Neuroscience. 2008, 155: 154-163. 10.1016/j.neuroscience.2008.05.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee KW, Kim JB, Seo JS, Kim TK, Im JY, Baek IS, Kim KS, Lee JK, Han PL: Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. J Neurochem. 2009, 108: 165-175. 10.1111/j.1471-4159.2008.05769.x.View ArticlePubMedGoogle Scholar
- Baum LW: Sex, hormones, and Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2005, 60: 736-743.View ArticlePubMedGoogle Scholar
- Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A: Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999, 53: 1992-1997.View ArticlePubMedGoogle Scholar
- Hy LX, Keller DM: Prevalence of AD among whites: a summary by levels of severity. Neurology. 2000, 55: 198-204.View ArticlePubMedGoogle Scholar
- Kim JJ, Diamond DM: The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci. 2002, 3: 453-462. 10.1038/nrm832.PubMedGoogle Scholar
- Shors TJ, Chua C, Falduto J: Sex differences and opposite effects of stress on dendritic spine density in the male versus female hippocampus. J Neurosci. 2001, 21: 6292-6297.PubMedGoogle Scholar
- Bangasser DA, Shors TJ: The hippocampus is necessary for enhancements and impairments of learning following stress. Nat Neurosci. 2007, 10: 1401-1403. 10.1038/nn1973.PubMed CentralView ArticlePubMedGoogle Scholar
- Waddell J, Bangasser DA, Shors TJ: The basolateral nucleus of the amygdala is necessary to induce the opposing effects of stressful experience on learning in males and females. J Neurosci. 2008, 28: 5290-5294. 10.1523/JNEUROSCI.1129-08.2008.PubMed CentralView ArticlePubMedGoogle Scholar
- Fukumoto H, Cheung BS, Hyman BT, Irizarry MC: β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002, 59: 1381-1389. 10.1001/archneur.59.9.1381.View ArticlePubMedGoogle Scholar
- Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y: Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003, 9: 3-4. 10.1038/nm0103-3.View ArticlePubMedGoogle Scholar
- Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y: Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA. 2004, 101: 3632-3637. 10.1073/pnas.0205689101.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, Irizarry MC, Hyman BT: Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res. 2007, 1161: 116-123. 10.1016/j.brainres.2007.05.050.View ArticlePubMedGoogle Scholar
- Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006, 26: 10129-10140. 10.1523/JNEUROSCI.1202-06.2006.View ArticlePubMedGoogle Scholar
- Chang RC, Wong AK, Ng HK, Hugon J: Phosphorylation of eukaryotic initiation factor-2α (eIF2α) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport. 2002, 13: 2429-2432. 10.1097/00001756-200212200-00011.View ArticlePubMedGoogle Scholar
- O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S, Lichtenthaler SF, Hebert SS, De Strooper B, Haass C, Bennett DA, Vassar R: Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron. 2008, 60: 988-1009. 10.1016/j.neuron.2008.10.047.PubMed CentralView ArticlePubMedGoogle Scholar
- Devi L, Ohno M: Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One. 2010, 5: e12974-10.1371/journal.pone.0012974.PubMed CentralView ArticlePubMedGoogle Scholar
- McGowan E, Eriksen J, Hutton M: A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22: 281-289. 10.1016/j.tig.2006.03.007.View ArticlePubMedGoogle Scholar
- Gotz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F: Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry. 2004, 9: 664-683.PubMedGoogle Scholar
- Gotz J, Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008, 9: 532-544. 10.1038/nrn2420.View ArticlePubMedGoogle Scholar
- Morrissette DA, Parachikova A, Green KN, LaFerla FM: Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem. 2009, 284: 6033-6037. 10.1074/jbc.R800030200.View ArticlePubMedGoogle Scholar
- McDowell I: Alzheimer's disease: insights from epidemiology. Aging (Milano). 2001, 13: 143-162.Google Scholar
- Qiu C, Kivipelto M, von Strauss E: Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009, 11: 111-128.PubMed CentralPubMedGoogle Scholar
- Findeis MA: The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacol Ther. 2007, 116: 266-286. 10.1016/j.pharmthera.2007.06.006.View ArticlePubMedGoogle Scholar
- McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005, 47: 191-199. 10.1016/j.neuron.2005.06.030.PubMed CentralView ArticlePubMedGoogle Scholar
- Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol. 2007, 8: 101-112. 10.1038/nrm2101.View ArticlePubMedGoogle Scholar
- de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H: MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med. 2004, 256: 205-223. 10.1111/j.1365-2796.2004.01381.x.View ArticlePubMedGoogle Scholar
- Sotiropoulos I, Cerqueira JJ, Catania C, Takashima A, Sousa N, Almeida OF: Stress and glucocorticoid footprints in the brain-the path from depression to Alzheimer's disease. Neurosci Biobehav Rev. 2008, 32: 1161-1173. 10.1016/j.neubiorev.2008.05.007.View ArticlePubMedGoogle Scholar
- Weiser MJ, Handa RJ: Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamic-pituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscience. 2009, 159: 883-895. 10.1016/j.neuroscience.2008.12.058.View ArticlePubMedGoogle Scholar
- Mizuno K, Giese KP: Towards a molecular understanding of sex differences in memory formation. Trends Neurosci. 2010, 33: 285-291. 10.1016/j.tins.2010.03.001.View ArticlePubMedGoogle Scholar
- Andreano JM, Cahill L: Sex influences on the neurobiology of learning and memory. Learn Mem. 2009, 16: 248-266. 10.1101/lm.918309.View ArticlePubMedGoogle Scholar
- Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP: BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem. 2010, 112: 1045-1053. 10.1111/j.1471-4159.2009.06528.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R: BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis. 2007, 26: 134-145. 10.1016/j.nbd.2006.12.008.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R: β-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci. 2007, 27: 3639-3649. 10.1523/JNEUROSCI.4396-06.2007.View ArticlePubMedGoogle Scholar
- Zhang X-M, Cai Y, Xiong K, Cai H, Luo X-G, Feng J-C, Clough RW, Struble RG, Patrylo PR, Yan X-X: β-Secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci. 2009, 30: 2271-2283. 10.1111/j.1460-9568.2009.07017.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Page G, Rioux Bilan A, Ingrand S, Lafay-Chebassier C, Pain S, Perault Pochat MC, Bouras C, Bayer T, Hugon J: Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease. Neuroscience. 2006, 139: 1343-1354. 10.1016/j.neuroscience.2006.01.047.View ArticlePubMedGoogle Scholar
- Kim HS, Choi Y, Shin KY, Joo Y, Lee YK, Jung SY, Suh YH, Kim JH: Swedish amyloid precursor protein mutation increases phosphorylation of eIF2α in vitro and in vivo. J Neurosci Res. 2007, 85: 1528-1537. 10.1002/jnr.21267.View ArticlePubMedGoogle Scholar
- Rossner S, Sastre M, Bourne K, Lichtenthaler SF: Transcriptional and translational regulation of BACE1 expression - implications for Alzheimer's disease. Prog Neurobiol. 2006, 79: 95-111. 10.1016/j.pneurobio.2006.06.001.View ArticlePubMedGoogle Scholar
- Wen Y, Yu WH, Maloney B, Bailey J, Ma J, Marie I, Maurin T, Wang L, Figueroa H, Herman M, Krishnamurthy P, Liu L, Planel E, Lau LF, Lahiri DK, Duff K: Transcriptional regulation of β-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008, 57: 680-690. 10.1016/j.neuron.2008.02.024.PubMed CentralView ArticlePubMedGoogle Scholar
- Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK: Gene structure and organization of the human β-secretase (BACE) promoter. FASEB J. 2004, 18: 1034-1036.PubMedGoogle Scholar
- Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM: Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006, 26: 9047-9056. 10.1523/JNEUROSCI.2797-06.2006.View ArticlePubMedGoogle Scholar
- Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, Brent G, Ravid R, Johnston JA: BACE1 mRNA Expression in Alzheimer's Disease Postmortem Brain Tissue. J Alzheimers Dis. 2010,Google Scholar
- Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G: Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol. 2002, 51: 783-786. 10.1002/ana.10208.View ArticlePubMedGoogle Scholar
- Borghi R, Patriarca S, Traverso N, Piccini A, Storace D, Garuti A, Gabriella C, Patrizio O, Massimo T: The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging. 2007, 28: 1009-1014. 10.1016/j.neurobiolaging.2006.05.004.View ArticlePubMedGoogle Scholar
- Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, Mudge AW, Jazin E, Cairns NJ: β-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. Brain Res Mol Brain Res. 2003, 116: 155-158. 10.1016/S0169-328X(03)00233-X.View ArticlePubMedGoogle Scholar
- Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA: Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med. 1998, 4: 827-831. 10.1038/nm0798-827.View ArticlePubMedGoogle Scholar
- Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ: Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008, 14: 837-842. 10.1038/nm1782.PubMed CentralView ArticlePubMedGoogle Scholar
- Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML: Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997, 387: 500-505. 10.1038/387500a0.View ArticlePubMedGoogle Scholar
- Choi SH, Park CH, Koo JW, Seo JH, Kim HS, Jeong SJ, Lee JH, Kim SS, Suh YH: Memory impairment and cholinergic dysfunction by centrally administered Aβ and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J. 2001, 15: 1816-1818. 10.1096/fj.00-0104com.View ArticlePubMedGoogle Scholar
- Lee KW, Im JY, Song JS, Lee SH, Lee HJ, Ha HY, Koh JY, Gwag BJ, Yang SD, Paik SG, Han PL: Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein. Neurobiol Dis. 2006, 22: 10-24. 10.1016/j.nbd.2005.09.011.View ArticlePubMedGoogle Scholar
- Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, Almeida OF: The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009, 14: 95-105. 10.1038/sj.mp.4002101.View ArticlePubMedGoogle Scholar
- Li WZ, Li WP, Yao YY, Zhang W, Yin YY, Wu GC, Gong HL: Glucocorticoids increase impairments in learning and memory due to elevated amyloid precursor protein expression and neuronal apoptosis in 12-month old mice. Eur J Pharmacol. 2010, 628: 108-115. 10.1016/j.ejphar.2009.11.045.View ArticlePubMedGoogle Scholar
- Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, Lawlor BA: Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry. 1998, 155: 286-289.View ArticlePubMedGoogle Scholar
- Masugi F, Ogihara T, Sakaguchi K, Otsuka A, Tsuchiya Y, Morimoto S, Kumahara Y, Saeki S, Nishide M: High plasma levels of cortisol in patients with senile dementia of the Alzheimer's type. Methods Find Exp Clin Pharmacol. 1989, 11: 707-710.PubMedGoogle Scholar
- Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC: Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006, 163: 2164-2169. 10.1176/appi.ajp.163.12.2164.PubMed CentralView ArticlePubMedGoogle Scholar
- Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF: Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006, 23: 251-260. 10.1111/j.1460-9568.2005.04551.x.View ArticlePubMedGoogle Scholar
- Kimura R, Devi L, Ohno M: Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J Neurochem. 2010, 113: 248-261. 10.1111/j.1471-4159.2010.06608.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Devi L, Ohno M: Genetic reductions of β-site amyloid precursor protein-cleaving enzyme 1 and amyloid-β ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Eur J Neurosci. 2010, 31: 110-118. 10.1111/j.1460-9568.2009.07031.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Franklin KBJ, Paxinos G: The Mouse Brain in Stereotaxic Coordinates. 2008, New York: Academic PressGoogle Scholar
- Alldred MJ, Che S, Ginsberg SD: Terminal Continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. Int J Mol Sci. 2008, 9: 2091-2104. 10.3390/ijms9112091.PubMed CentralView ArticlePubMedGoogle Scholar
- Ginsberg SD: Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol. 2008, 439: 147-158. full_text.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.